Eighty-nine patients with untreated primary neuroblastomas were studied to determine the relation between the number of copies of the N-myc oncogene and survival without disease progression. Genomic amplification (3 to 300 copies) of N-myc was detected in 2 of 16 tumors in Stage II, 13 of 20 in Stage III, and 19 of 40 in Stage IV; in contrast, 8 Stage I and 5 Stage IV-S tumors all had 1 copy of the gene (P less than 0.01). Analysis of progression-free survival in all patients revealed that amplification of N-myc was associated with the worst prognosis (P less than 0.0001); the estimated progression-free survival at 18 months was 70 per cent, 30 per cent, and 5 per cent for patients whose tumors had 1, 3 to 10, or more than 10 N-myc copies, respectively. Of 16 Stage II tumors, 2 with amplification metastasized, whereas only 1 of 14 without amplification did so (P = 0.03). Stage IV tumors with amplification progressed most rapidly: nine months after diagnosis the estimated progression-free survival was 61 per cent, 47 per cent, and 0 per cent in patients whose tumors had 1, 3 to 10, or more than 10 copies, respectively (P less than 0.0001). These results suggest that genomic amplification of N-myc may have a key role in determining the aggressiveness of neuroblastomas.
This article has been cited by other articles:
Moore, H C, Wood, K M, Jackson, M S, Lastowska, M A, Hall, D, Imrie, H, Redfern, C P F, Lovat, P E, Ponthan, F, O'Toole, K, Lunec, J, Tweddle, D A
(2008). Histological profile of tumours from MYCN transgenic mice. J. Clin. Pathol.
61: 1098-1103
[Abstract][Full Text]
Cattelani, S., Defferrari, R., Marsilio, S., Bussolari, R., Candini, O., Corradini, F., Ferrari-Amorotti, G., Guerzoni, C., Pecorari, L., Menin, C., Bertorelle, R., Altavista, P., McDowell, H. P., Boldrini, R., Dominici, C., Tonini, G. P., Raschella, G., Calabretta, B.
(2008). Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients. Clin. Cancer Res.
14: 3248-3253
[Abstract][Full Text]
Schneiderman, J., London, W. B., Brodeur, G. M., Castleberry, R. P., Look, A. T., Cohn, S. L.
(2008). Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. JCO
26: 913-918
[Abstract][Full Text]
Stock, C., Bozsaky, E., Watzinger, F., Poetschger, U., Orel, L., Lion, T., Kowalska, A., Ambros, P. F.
(2008). Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization. Am. J. Pathol.
172: 203-214
[Abstract][Full Text]
Alvarez-Rodriguez, R., Barzi, M., Berenguer, J., Pons, S.
(2007). Bone Morphogenetic Protein 2 Opposes Shh-mediated Proliferation in Cerebellar Granule Cells through a TIEG-1-based Regulation of Nmyc. J. Biol. Chem.
282: 37170-37180
[Abstract][Full Text]
Laneve, P., Di Marcotullio, L., Gioia, U., Fiori, M. E., Ferretti, E., Gulino, A., Bozzoni, I., Caffarelli, E.
(2007). The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc. Natl. Acad. Sci. USA
104: 7957-7962
[Abstract][Full Text]
Kuuselo, R., Savinainen, K., Azorsa, D. O., Basu, G. D., Karhu, R., Tuzmen, S., Mousses, S., Kallioniemi, A.
(2007). Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. Cancer Res.
67: 1943-1949
[Abstract][Full Text]
Zeng, Y., Huebener, N., Fest, S., Weixler, S., Schroeder, U., Gaedicke, G., Xiang, R., Schramm, A., Eggert, A., Reisfeld, R. A., Lode, H. N.
(2007). Fractalkine (CX3CL1)- and Interleukin-2-Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells. Cancer Res.
67: 2331-2338
[Abstract][Full Text]
Li, H., Dutuor, A., Tao, L., Fu, X., Zhang, X.
(2007). Virotherapy with a Type 2 Herpes Simplex Virus-Derived Oncolytic Virus Induces Potent Antitumor Immunity against Neuroblastoma. Clin. Cancer Res.
13: 316-322
[Abstract][Full Text]
Moreau, L. A., McGrady, P., London, W. B., Shimada, H., Cohn, S. L., Maris, J. M., Diller, L., Look, A. T., George, R. E.
(2006). Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study.. Clin. Cancer Res.
12: 5693-5697
[Abstract][Full Text]
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., Seeger, R. C.
(2006). Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification.. JNCI J Natl Cancer Inst
98: 1193-1203
[Abstract][Full Text]
Fischer, M., Oberthuer, A., Brors, B., Kahlert, Y., Skowron, M., Voth, H., Warnat, P., Ernestus, K., Hero, B., Berthold, F.
(2006). Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome. Clin. Cancer Res.
12: 5118-5128
[Abstract][Full Text]
Gupta, A., Williams, B. R.G., Hanash, S. M., Rawwas, J.
(2006). Cellular Retinoic Acid-Binding Protein II Is a Direct Transcriptional Target of MycN in Neuroblastoma. Cancer Res.
66: 8100-8108
[Abstract][Full Text]
Chesler, L., Schlieve, C., Goldenberg, D. D., Kenney, A., Kim, G., McMillan, A., Matthay, K. K., Rowitch, D., Weiss, W. A.
(2006). Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Res.
66: 8139-8146
[Abstract][Full Text]
Wang, Q., Diskin, S., Rappaport, E., Attiyeh, E., Mosse, Y., Shue, D., Seiser, E., Jagannathan, J., Shusterman, S., Bansal, M., Khazi, D., Winter, C., Okawa, E., Grant, G., Cnaan, A., Zhao, H., Cheung, N.-K., Gerald, W., London, W., Matthay, K. K., Brodeur, G. M., Maris, J. M.
(2006). Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.. Cancer Res.
66: 6050-6062
[Abstract][Full Text]
Haber, M., Smith, J., Bordow, S. B., Flemming, C., Cohn, S. L., London, W. B., Marshall, G. M., Norris, M. D.
(2006). Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. JCO
24: 1546-1553
[Abstract][Full Text]
Tang, X. X., Zhao, H., Kung, B., Kim, D. Y., Hicks, S. L., Cohn, S. L., Cheung, N.-K., Seeger, R. C., Evans, A. E., Ikegaki, N.
(2006). The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma.. Cancer Res.
66: 2826-2833
[Abstract][Full Text]
Navarro, S., Amann, G., Beiske, K., Cullinane, C. J., d'Amore, E. S.G., Gambini, C., Mosseri, V., De Bernardi, B., Michon, J., Peuchmaur, M.
(2006). Prognostic Value of International Neuroblastoma Pathology Classification in Localized Resectable Peripheral Neuroblastic Tumors: A Histopathologic Study of Localized Neuroblastoma European Study Group 94.01 Trial and Protocol. JCO
24: 695-699
[Abstract][Full Text]
Hsu, W.-M., Jen, Y.-M., Lee, H., Kuo, M.-L., Tsao, P.-N., Chen, C.-N., Lai, D.-M., Lin, M.-T., Lai, H.-S., Chen, W.-J., Hsieh, F.-J.
(2006). The Influence of Biologic Factors on the Surgical Decision in Advanced Neuroblastoma. Ann. Surg. Oncol.
13: 238-244
[Abstract][Full Text]
Bagatell, R., Rumcheva, P., London, W. B., Cohn, S. L., Look, A. T., Brodeur, G. M., Frantz, C., Joshi, V., Thorner, P., Rao, P.V., Castleberry, R., Bowman, L. C.
(2005). Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. JCO
23: 8819-8827
[Abstract][Full Text]
Attiyeh, E. F., London, W. B., Mosse, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., Brodeur, G. M., Cohn, S. L., Matthay, K. K., Maris, J. M., the Children's Oncology Group,
(2005). Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma.. NEJM
353: 2243-2253
[Abstract][Full Text]
George, R. E., London, W. B., Cohn, S. L., Maris, J. M., Kretschmar, C., Diller, L., Brodeur, G. M., Castleberry, R. P., Look, A. T.
(2005). Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. JCO
23: 6466-6473
[Abstract][Full Text]
London, W.B., Castleberry, R.P., Matthay, K.K., Look, A.T., Seeger, R.C., Shimada, H., Thorner, P., Brodeur, G., Maris, J.M., Reynolds, C.P., Cohn, S.L.
(2005). Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group. JCO
23: 6459-6465
[Abstract][Full Text]
Schmidt, M. L., Lal, A., Seeger, R. C., Maris, J. M., Shimada, H., O'Leary, M., Gerbing, R. B., Matthay, K. K.
(2005). Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study. JCO
23: 6474-6480
[Abstract][Full Text]
Giannini, G., Cerignoli, F., Mellone, M., Massimi, I., Ambrosi, C., Rinaldi, C., Dominici, C., Frati, L., Screpanti, I., Gulino, A.
(2005). High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma. Cancer Res.
65: 8308-8316
[Abstract][Full Text]
Perini, G., Diolaiti, D., Porro, A., Della Valle, G.
(2005). In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc. Natl. Acad. Sci. USA
102: 12117-12122
[Abstract][Full Text]
Gotoh, T., Hosoi, H., Iehara, T., Kuwahara, Y., Osone, S., Tsuchiya, K., Ohira, M., Nakagawara, A., Kuroda, H., Sugimoto, T.
(2005). Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction. JCO
23: 5205-5210
[Abstract][Full Text]
Maris, J. M., Hii, G., Gelfand, C. A., Varde, S., White, P. S., Rappaport, E., Surrey, S., Fortina, P.
(2005). Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res
15: 1168-1176
[Abstract][Full Text]
Aoyama, M., Ozaki, T., Inuzuka, H., Tomotsune, D., Hirato, J., Okamoto, Y., Tokita, H., Ohira, M., Nakagawara, A.
(2005). LMO3 Interacts with Neuronal Transcription Factor, HEN2, and Acts as an Oncogene in Neuroblastoma. Cancer Res.
65: 4587-4597
[Abstract][Full Text]
Vandesompele, J., Baudis, M., De Preter, K., Van Roy, N., Ambros, P., Bown, N., Brinkschmidt, C., Christiansen, H., Combaret, V., Lastowska, M., Nicholson, J., O'Meara, A., Plantaz, D., Stallings, R., Brichard, B., Van den Broecke, C., De Bie, S., De Paepe, A., Laureys, G., Speleman, F.
(2005). Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma. JCO
23: 2280-2299
[Abstract][Full Text]
Alaminos, M., Davalos, V., Ropero, S., Setien, F., Paz, M. F., Herranz, M., Fraga, M. F., Mora, J., Cheung, N.-K. V., Gerald, W. L., Esteller, M.
(2005). EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. Cancer Res.
65: 2565-2571
[Abstract][Full Text]
Norris, M. D., Smith, J., Tanabe, K., Tobin, P., Flemming, C., Scheffer, G. L., Wielinga, P., Cohn, S. L., London, W. B., Marshall, G. M., Allen, J. D., Haber, M.
(2005). Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Molecular Cancer Therapeutics
4: 547-553
[Abstract][Full Text]
Uccini, S., Mannarino, O., McDowell, H. P., Pauser, U., Vitali, R., Natali, P. G., Altavista, P., Andreano, T., Coco, S., Boldrini, R., Bosco, S., Clerico, A., Cozzi, D., Donfrancesco, A., Inserra, A., Kokai, G., Losty, P. D., Nicotra, M. R., Raschella, G., Tonini, G. P., Dominici, C.
(2005). Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors. Clin. Cancer Res.
11: 380-389
[Abstract][Full Text]
Yang, Q., Zage, P., Kagan, D., Tian, Y., Seshadri, R., Salwen, H. R., Liu, S., Chlenski, A., Cohn, S. L.
(2004). Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma. Clin. Cancer Res.
10: 8493-8500
[Abstract][Full Text]
Roberts, S. S., Mori, M., Pattee, P., Lapidus, J., Mathews, R., O'Malley, J. P., Hsieh, Y. C., Turner, M. A., Wang, Z., Tian, Q., Rodland, M. J., Reynolds, C. P., Seeger, R. C., Nagalla, S. R.
(2004). GABAergic System Gene Expression Predicts Clinical Outcome in Patients With Neuroblastoma. JCO
22: 4127-4134
[Abstract][Full Text]
Yang, H. W., Kutok, J. L., Lee, N. H., Piao, H. Y., Fletcher, C. D. M., Kanki, J. P., Look, A. T.
(2004). Targeted Expression of Human MYCN Selectively Causes Pancreatic Neuroendocrine Tumors in Transgenic Zebrafish. Cancer Res.
64: 7256-7262
[Abstract][Full Text]
Ciani, E., Severi, S., Contestabile, A., Bartesaghi, R., Contestabile, A.
(2004). Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. J. Cell Sci.
117: 4727-4737
[Abstract][Full Text]
Don, S., Verrills, N. M., Liaw, T. Y.E., Liu, M. L.M., Norris, M. D., Haber, M., Kavallaris, M.
(2004). Neuronal-associated microtubule proteins class III {beta}-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs. Molecular Cancer Therapeutics
3: 1137-1146
[Abstract][Full Text]
Alaminos, M., Davalos, V., Cheung, N.-K. V., Gerald, W. L., Esteller, M.
(2004). Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma. JNCI J Natl Cancer Inst
96: 1208-1219
[Abstract][Full Text]
Yang, Q., Liu, S., Tian, Y., Hasan, C., Kersey, D., Salwen, H. R., Chlenski, A., Perlman, E. J., Cohn, S. L.
(2004). Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma. Cancer Res.
64: 4531-4538
[Abstract][Full Text]
Irshad, S., Pedley, R. B., Anderson, J., Latchman, D. S., Budhram-Mahadeo, V.
(2004). The Brn-3b Transcription Factor Regulates the Growth, Behavior, and Invasiveness of Human Neuroblastoma Cells in Vitro and in Vivo. J. Biol. Chem.
279: 21617-21627
[Abstract][Full Text]
Metelitsa, L. S., Wu, H.-W., Wang, H., Yang, Y., Warsi, Z., Asgharzadeh, S., Groshen, S., Wilson, S. B., Seeger, R. C.
(2004). Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2. JEM
199: 1213-1221
[Abstract][Full Text]
Hirasawa, A., Aoki, D., Inoue, J., Imoto, I., Susumu, N., Sugano, K., Nozawa, S., Inazawa, J.
(2003). Unfavorable Prognostic Factors Associated with High Frequency of Microsatellite Instability and Comparative Genomic Hybridization Analysis in Endometrial Cancer. Clin. Cancer Res.
9: 5675-5682
[Abstract][Full Text]
Hettmer, S., Malott, C., Woods, W., Ladisch, S., Kaucic, K.
(2003). Biological Stratification of Human Neuroblastoma by Complex "B" Pathway Ganglioside Expression. Cancer Res.
63: 7270-7276
[Abstract][Full Text]
Burkhart, C. A., Cheng, A. J., Madafiglio, J., Kavallaris, M., Mili, M., Marshall, G. M., Weiss, W. A., Khachigian, L. M., Norris, M. D., Haber, M.
(2003). Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. JNCI J Natl Cancer Inst
95: 1394-1403
[Abstract][Full Text]
Hackett, C. S., Hodgson, J. G., Law, M. E., Fridlyand, J., Osoegawa, K., de Jong, P. J., Nowak, N. J., Pinkel, D., Albertson, D. G., Jain, A., Jenkins, R., Gray, J. W., Weiss, W. A.
(2003). Genome-wide Array CGH Analysis of Murine Neuroblastoma Reveals Distinct Genomic Aberrations which Parallel those in Human Tumors. Cancer Res.
63: 5266-5273
[Abstract][Full Text]
Alaminos, M., Mora, J., Cheung, N.-K. V., Smith, A., Qin, J., Chen, L., Gerald, W. L.
(2003). Genome-wide Analysis of Gene Expression Associated with MYCN in Human Neuroblastoma. Cancer Res.
63: 4538-4546
[Abstract][Full Text]
Tajiri, T., Liu, X., Thompson, P. M., Tanaka, S., Suita, S., Zhao, H., Maris, J. M., Prendergast, G. C., Hogarty, M. D.
(2003). Expression of a MYCN-interacting Isoform of the Tumor Suppressor BIN1 Is Reduced in Neuroblastomas with Unfavorable Biological Features. Clin. Cancer Res.
9: 3345-3355
[Abstract][Full Text]
Tokiwa, K., Fumino, S., Ono, S., Iwai, N.
(2003). Results of Retroperitoneal Lymphadenectomy in the Treatment of Abdominal Neuroblastoma. Arch Surg
138: 711-715
[Abstract][Full Text]
Ambros, I.M., Benard, J., Boavida, M., Bown, N., Caron, H., Combaret, V., Couturier, J., Darnfors, C., Delattre, O., Freeman-Edward, J., Gambini, C., Gross, N., Hattinger, C.M., Luegmayr, A., Lunec, J., Martinsson, T., Mazzocco, K., Navarro, S., Noguera, R., O'Neill, S., Potschger, U., Rumpler, S., Speleman, F., Tonini, G.P., Valent, A., Van Roy, N., Amann, G., De Bernardi, B., Kogner, P., Ladenstein, R., Michon, J., Pearson, A.D.J., Ambros, P.F.
(2003). Quality Assessment of Genetic Markers Used for Therapy Stratification. JCO
21: 2077-2084
[Abstract][Full Text]
Weinstein, J. L., Katzenstein, H. M., Cohn, S. L.
(2003). Advances in the Diagnosis and Treatment of Neuroblastoma. The Oncologist
8: 278-292
[Abstract][Full Text]
Saito-Ohara, F., Imoto, I., Inoue, J., Hosoi, H., Nakagawara, A., Sugimoto, T., Inazawa, J.
(2003). PPM1D Is a Potential Target for 17q Gain in Neuroblastoma. Cancer Res.
63: 1876-1883
[Abstract][Full Text]
Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., Yang, Q., Salwen, H. R., Farrer, R., Bray, J., Cohn, S. L.
(2002). SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis. Cancer Res.
62: 7357-7363
[Abstract][Full Text]
Combaret, V., Audoynaud, C., Iacono, I., Favrot, M.-C., Schell, M., Bergeron, C., Puisieux, A.
(2002). Circulating MYCN DNA as a Tumor-specific Marker in Neuroblastoma Patients. Cancer Res.
62: 3646-3648
[Abstract][Full Text]
Kletzel, M., Katzenstein, H. M., Haut, P. R., Yu, A. L., Morgan, E., Reynolds, M., Geissler, G., Marymount, M. H., Liu, D., Kalapurakal, J. A., Shore, R. M., Bardo, D. M.E., Schmoldt, J., Rademaker, A. W., Cohn, S. L.
(2002). Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study. JCO
20: 2284-2292
[Abstract][Full Text]
Karamouzis, M. V., Gorgoulis, V. G., Papavassiliou, A. G.
(2002). Transcription Factors and Neoplasia: Vistas in Novel Drug Design. Clin. Cancer Res.
8: 949-961
[Abstract][Full Text]
Bown, N
(2001). Neuroblastoma tumour genetics: clinical and biological aspects. J. Clin. Pathol.
54: 897-910
[Abstract][Full Text]
Walentinsson, A., Helou, K., Wallenius, V., Hedrich, H. J., Szpirer, C., Levan, G.
(2001). Independent Amplification of Two Gene Clusters on Chromosome 4 in Rat Endometrial Cancer: Identification and Molecular Characterization. Cancer Res.
61: 8263-8273
[Abstract][Full Text]
Omura-Minamisawa, M., Diccianni, M. B., Chang, R. C., Batova, A., Bridgeman, L. J., Schiff, J., Cohn, S. L., London, W. B., Yu, A. L.
(2001). p16/p14ARF Cell Cycle Regulatory Pathways in Primary Neuroblastoma: p16 Expression Is Associated with Advanced Stage Disease. Clin. Cancer Res.
7: 3481-3490
[Abstract][Full Text]
Bleoo, S., Sun, X., Hendzel, M. J., Rowe, J. M., Packer, M., Godbout, R.
(2001). Association of Human DEAD Box Protein DDX1 with a Cleavage Stimulation Factor Involved in 3'-End Processing of Pre-mRNA. Mol. Biol. Cell
12: 3046-3059
[Abstract][Full Text]
Sato, Y., Sasaki, H., Kondo, S., Fukai, I., Kiriyama, M., Yamakawa, Y., Fujii, Y.
(2001). Expression of the cdc25B mRNA Correlated with that of N-myc in Neuroblastoma. Jpn J Clin Oncol
31: 428-431
[Abstract][Full Text]
Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., Reynolds, C. P.
(2001). Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines. Cancer Res.
61: 6185-6193
[Abstract][Full Text]
Hoon, D. S. B., Kuo, C. T., Wen, S., Wang, H., Metelitsa, L., Reynolds, C. P., Seeger, R. C.
(2001). Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow. Am. J. Pathol.
159: 493-500
[Abstract][Full Text]
Grotzer, M. A., Hogarty, M. D., Janss, A. J., Liu, X., Zhao, H., Eggert, A., Sutton, L. N., Rorke, L. B., Brodeur, G. M., Phillips, P. C.
(2001). MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma. Clin. Cancer Res.
7: 2425-2433
[Abstract][Full Text]
Amitay, R., Nass, D., Meitar, D., Goldberg, I., Davidson, B., Trakhtenbrot, L., Brok-Simoni, F., Ben-Ze'ev, A., Rechavi, G., Kaufmann, Y.
(2001). Reduced Expression of Plakoglobin Correlates with Adverse Outcome in Patients with Neuroblastoma. Am. J. Pathol.
159: 43-49
[Abstract][Full Text]
Mora, J., Gerald, W. L., Qin, J., Cheung, N.-K. V.
(2001). Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience. The Oncologist
6: 263-268
[Abstract][Full Text]
Kammen, B. F., Matthay, K. K., Pacharn, P., Gerbing, R., Brasch, R. C., Gooding, C. A.
(2001). Pulmonary Metastases at Diagnosis of Neuroblastoma in Pediatric Patients: CT Findings and Prognosis. Am. J. Roentgenol.
176: 755-759
[Abstract][Full Text]
Katzenstein, H. M., Kent, P. M., London, W. B., Cohn, S. L.
(2001). Treatment and Outcome of 83 Children With Intraspinal Neuroblastoma: The Pediatric Oncology Group Experience. JCO
19: 1047-1055
[Abstract][Full Text]
Seeger, R. C., Reynolds, C. P., Gallego, R., Stram, D. O., Gerbing, R. B., Matthay, K. K.
(2000). Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children's Cancer Group Study. JCO
18: 4067-4076
[Abstract][Full Text]
Matthay, K. K.
(2000). MYCN Expression in Neuroblastoma: A Mixed Message?. JCO
18: 3591-3594
[Full Text]
Cohn, S. L., London, W. B., Huang, D., Katzenstein, H. M., Salwen, H. R., Reinhart, T., Madafiglio, J., Marshall, G. M., Norris, M. D., Haber, M.
(2000). MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN. JCO
18: 3604-3613
[Abstract][Full Text]
Huang, D., Rutkowski, J. L., Brodeur, G. M., Chou, P. M., Kwiatkowski, J. L., Babbo, A., Cohn, S. L.
(2000). Schwann Cell-conditioned Medium Inhibits Angiogenesis. Cancer Res.
60: 5966-5971
[Abstract][Full Text]
Raggi, C. C., Maggi, M., Renzi, D., Calabrò, A., Bagnoni, M. L., Scaruffi, P., Tonini, G. P., Pazzagli, M., De Bernardi, B., Bernini, G., Serio, M., Orlando, C.
(2000). Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome. J. Clin. Endocrinol. Metab.
85: 3866-3873
[Abstract][Full Text]
Nishihira, H., Toyoda, Y., Tanaka, Y., Ijiri, R., Aida, N., Takeuchi, M., Ohnuma, K., Kigasawa, H., Kato, K., Nishi, T.
(2000). Natural Course of Neuroblastoma Detected by Mass Screening: A 5-Year Prospective Study at a Single Institution. JCO
18: 3012-3017
[Abstract][Full Text]
Matsunaga, T., Shirasawa, H., Hishiki, T., Yoshida, H., Kouchi, K., Ohtsuka, Y., Kawamura, K., Etoh, T., Ohnuma, N.
(2000). Enhanced Expression of N-myc Messenger RNA in Neuroblastomas Found by Mass Screening. Clin. Cancer Res.
6: 3199-3204
[Abstract][Full Text]
Maris, J. M., Weiss, M. J., Guo, C., Gerbing, R. B., Stram, D. O., White, P. S., Hogarty, M. D., Sulman, E. P., Thompson, P. M., Lukens, J. N., Matthay, K. K., Seeger, R. C., Brodeur, G. M.
(2000). Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study. JCO
18: 1888-1899
[Abstract][Full Text]
Sarkar, A. K., Nuchtern, J. G.
(2000). Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes. Cancer Res.
60: 1908-1913
[Abstract][Full Text]
Bastian, B. C., Kashani-Sabet, M., Hamm, H., Godfrey, T., Moore, D. H. II, Bröcker, E.-B., LeBoit, P. E., Pinkel, D.
(2000). Gene Amplifications Characterize Acral Melanoma and Permit the Detection of Occult Tumor Cells in the Surrounding Skin. Cancer Res.
60: 1968-1973
[Abstract][Full Text]
Schmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., Matthay, K. K.
(2000). Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study. JCO
18: 1260-1268
[Abstract][Full Text]
Yokota, J.
(2000). Tumor progression and metastasis. Carcinogenesis
21: 497-503
[Abstract][Full Text]
Nickerson, H. J., Matthay, K. K., Seeger, R. C., Brodeur, G. M., Shimada, H., Perez, C., Atkinson, J. B., Selch, M., Gerbing, R. B., Stram, D. O., Lukens, J.
(2000). Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children’s Cancer Group Study. JCO
18: 477-477
[Abstract][Full Text]
Mora, J., Cheung, N.-K. V., Kushner, B. H., LaQuaglia, M. P., Kramer, K., Fazzari, M., Heller, G., Chen, L., Gerald, W. L.
(2000). Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. J. Mol. Diagn.
2: 37-46
[Abstract][Full Text]
Perez, C. A., Matthay, K. K., Atkinson, J. B., Seeger, R. C., Shimada, H., Haase, G. M., Stram, D. O., Gerbing, R. B., Lukens, J. N.
(2000). Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children’s Cancer Group Study. JCO
18: 18-18
[Abstract][Full Text]
Canete, A., Navarro, S., Bermudez, J., Pellin, A., Castel, V., Llombart-Bosch, A.
(2000). Angiogenesis in Neuroblastoma: Relationship to Survival and Other Prognostic Factors in a Cohort of Neuroblastoma Patients. JCO
18: 27-27
[Abstract][Full Text]
Raggi, C. C., Bagnoni, M. L., Tonini, G. P., Maggi, M., Vona, G., Pinzani, P., Mazzocco, K., De Bernardi, B., Pazzagli, M., Orlando, C.
(1999). Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System. Clin. Chem.
45: 1918-1924
[Abstract][Full Text]
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., Reynolds, C. P., The Children's Cancer Group,
(1999). Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. NEJM
341: 1165-1173
[Abstract][Full Text]
Kawa, K., Ohnuma, N., Kaneko, M., Yamamoto, K., Etoh, T., Mugishima, H., Ohhira, M., Yokoyama, J., Bessho, F., Honna, T., Yoshizawa, J., Nakada, K., Iwafuchi, M., Nozaki, T., Mimaya, J., Sawada, T., Nakamura, T., Miyata, H., Yamato, K., Tsuchida, Y.
(1999). Long-Term Survivors of Advanced Neuroblastoma With MYCN Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months. JCO
17: 3216-3220
[Abstract][Full Text]
Maris, J. M., Matthay, K. K.
(1999). Molecular Biology of Neuroblastoma. JCO
17: 2264-2264
[Abstract][Full Text]
Raschella, G., Cesi, V., Amendola, R., Negroni, A., Tanno, B., Altavista, P., Paolo Tonini, G., De Bernardi, B., Calabretta, B.
(1999). Expression of B-myb in Neuroblastoma Tumors Is a Poor Prognostic Factor Independent from MYCN Amplification. Cancer Res.
59: 3365-3368
[Abstract][Full Text]
Cohn, S. L.
(1999). Diagnosis and Classification of the Small Round-Cell Tumors of Childhood. Am. J. Pathol.
155: 11-15
[Full Text]
Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D.J., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., Speleman, F., Nicholson, J., Bernheim, A., Betts, D. R., Vandesompele, J., Van Roy, N.
(1999). Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma. NEJM
340: 1954-1961
[Abstract][Full Text]
Chambery, D., Mohseni-Zadeh, S., Galle, B. d., Babajko, S.
(1999). N-myc Regulation of Type I Insulin-like Growth Factor Receptor in a Human Neuroblastoma Cell Line. Cancer Res.
59: 2898-2902
[Abstract][Full Text]
Huhn, S. L., Mohapatra, G., Bollen, A., Lamborn, K., Prados, M. D., Feuerstein, B. G.
(1999). Chromosomal Abnormalities in Glioblastoma Multiforme by Comparative Genomic Hybridization: Correlation with Radiation Treatment Outcome. Clin. Cancer Res.
5: 1435-1443
[Abstract][Full Text]
Giannini, G., Di Marcotullio, L., Ristori, E., Zani, M., Crescenzi, M., Scarpa, S., Piaggio, G., Vacca, A., Peverali, F. A., Diana, F., Screpanti, I., Frati, L., Gulino, A.
(1999). HMGI(Y) and HMGI-C Genes Are Expressed in Neuroblastoma Cell Lines and Tumors and Affect Retinoic Acid Responsiveness. Cancer Res.
59: 2484-2492
[Abstract][Full Text]
Sugiura, Y., Ma, L., Sun, B., Shimada, H., Laug, W. E., Seeger, R. C., DeClerck, Y. A.
(1999). The Plasminogen-Plasminogen Activator (PA) System in Neuroblastoma: Role of PA Inhibitor-1 in Metastasis. Cancer Res.
59: 1327-1336
[Abstract][Full Text]
Hiyama, E., Hiyama, K., Yokoyama, T., Fukuba, I., Yamaoka, H., Shay, J. W., Matsuura, Y.
(1999). Rapid Detection of MYCN Gene Amplification and Telomerase Expression in Neuroblastoma. Clin. Cancer Res.
5: 601-609
[Abstract][Full Text]
Ross, J. A., Davies, S. M.
(1999). Screening for Neuroblastoma: Progress and Pitfalls. Cancer Epidemiol. Biomarkers Prev.
8: 189-194
[Full Text]
Sivak, L. E., Pont-Kingdon, G., Le, K., Mayr, G., Tai, K.-F., Stevens, B. T., Carroll, W. L.
(1999). A Novel Intron Element Operates Posttranscriptionally To Regulate Human N-myc Expression. Mol. Cell. Biol.
19: 155-163
[Abstract][Full Text]
Chen, B.-F., Chen, M.-L., Liang, D.-C., Liu, H.-C., Chen, S.-H.
(1999). The Relationship of N-myc Amplification and Apoptosis in Neuroblastoma. INT J SURG PATHOL
7: 19-25
[Abstract]
Godbout, R., Packer, M., Bie, W.
(1998). Overexpression of a DEAD Box Protein (DDX1) in Neuroblastoma and Retinoblastoma Cell Lines. J. Biol. Chem.
273: 21161-21168
[Abstract][Full Text]
Previous
